A groundbreaking blood biomarker study reveals a new way to predict brain damage after cardiac arrest, offering hope for improved patient care. Led by researchers at Lund University, the international multicentre study, published in The Lancet Respiratory Medicine, highlights the potential of a novel blood test to revolutionize the treatment of cardiac arrest patients. With an estimated four million sudden cardiac arrests worldwide annually, this research could significantly impact patient outcomes.
The study's lead researcher, Marion Moseby Knappe, emphasizes the importance of this discovery: "This will transform care for these patients." The key lies in a simple blood test that can accurately predict the chances of survival and recovery, providing valuable insights for intensive care units.
The research team compared four brain damage biomarkers in the blood to assess their reliability in estimating brain damage severity in unconscious cardiac arrest patients. One of the biomarkers, neurofilament light (NFL), demonstrated remarkable accuracy, correctly identifying 92% of patient outcomes at six months post-cardiac arrest. This biomarker's ability to differentiate between major and minor brain damage and provide rapid results within 24 hours is a significant advancement.
Interestingly, NFL is already utilized as a brain biomarker in neurological disease care, such as MS. Another biomarker, GFAP, outperformed the currently used biomarkers in estimating brain damage extent. However, the study's authors stress that the blood test alone cannot determine the end of intensive care. It must be complemented by other diagnostic methods like X-ray and brain electrical activity analysis.
The study, conducted across 24 European hospitals, included 819 adult patients, with a significant majority being men. Blood samples were collected at various time points after hospital admission and analyzed using a standardized machine. This comprehensive approach strengthens the study's findings and their potential clinical application.
This research builds upon a larger international clinical trial, the Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest (TTM2 trial), which found no difference in survival rates or recovery between body cooling and normal temperature treatments. The findings challenge the current guidelines, suggesting that cooling may not be beneficial and opening up new avenues for research and treatment.
